Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 17/20 | 0.47 |
| ▸ | EGFR | P00533 | 6/20 | 0.47 |
| ▸ | BLK | P51451 | 2/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | TEC | P42680 | 1/20 | 0.47 |
| ▸ | TXK | P42681 | 1/20 | 0.47 |
| ▸ | BMX | P51813 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30303291 | 1.00 | TGM2 (0.50) | TGM2BTKEGFRBLKERBB2 | |
| SCHEMBL26086108 | 0.89 | MAPT (0.41) | BTKEGFRBLKERBB2RET | |
| SCHEMBL22677015 | 0.89 | TGM2 (0.53) | TGM2BTKEGFRBLKERBB2 | |
| SCHEMBL22675866 | 0.81 | FGFR1 (0.46) | TGM2BTKEGFRBLKERBB2 | |
| SCHEMBL22676399 | 0.79 | BTK (0.61) | BTKEGFRBLKERBB2RET | |
| SCHEMBL30304003 | 0.78 | MAP2K7 (0.46) | TGM2BTKEGFRBLKERBB2 | |
| SCHEMBL22677034 | 0.78 | MAP2K7 (0.46) | TGM2BTKEGFRBLKERBB2 | |
| SCHEMBL22677214 | 0.78 | TGM2 (0.55) | TGM2BTKEGFRERBB2KCNH2 | |
| SCHEMBL22677208 | 0.74 | BTK (0.39) | BTKEGFRBLKERBB2RET | |
| SCHEMBL22676650 | 0.73 | BTK (0.55) | BTKEGFRBLKERBB2RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306529-A2 | FGFR INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | D.E. SHAW RESEARCH, LLC | 2023-04-06 | — | — | US | disclosed |
| WO-2020231990-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192709-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | TGM2 529/4885BTK 39/4885EGFR 16/4885 |
| US-20230104574-A1 | FGFR INHIBITORS AND METHODS OF USE THEREOF | FGFR3, FGFR2, FGFR1 | TGM2 529/4885BTK 39/4885EGFR 16/4885 |
| US-11780845-B2 | FGFR inhibitors and methods of use thereof | FGFR3, FGFR2, FGFR1 | TGM2 529/4885BTK 39/4885EGFR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.